ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
fiercebiotech
July 31, 2018A phase 3 trial of RedHill Biopharma’s Crohn’s disease asset has met its primary endpoint. The study linked antibiotic cocktail RHB-104 to a higher rate of remission than placebo after 26 weeks, although the difference between the two arms shrunk later in
Pharma Sources Insight January 2025
